Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Lisata Therapeutics (Nasdaq: LSTA) has entered into a sponsored research agreement with the University of Cincinnati to study certepetide combined with bevacizumab for treating endometriosis. The research aims to leverage certepetide's selective targeting of endometrial tissue through surface integrin and neuropilin-1 receptors. While bevacizumab has shown efficacy in endometriosis treatment, its high dosage requirements cause systemic side effects. The partnership targets endometriosis, a condition affecting 6.5 million U.S. women, characterized by uterine tissue growth outside the uterus, causing pain and fertility issues.
Lisata Therapeutics (Nasdaq: LSTA) ha stipulato un accordo di ricerca sponsorizzata con l'Università di Cincinnati per studiare certepetide combinato con bevacizumab nel trattamento dell'endometriosi. La ricerca mira a sfruttare il targeting selettivo di certepetide sul tessuto endometriale attraverso i recettori integrinici di superficie e neuropiline-1. Sebbene il bevacizumab abbia dimostrato efficacia nel trattamento dell'endometriosi, i requisiti di dosaggio elevati causano effetti collaterali sistemici. La partnership si concentra sull'endometriosi, una condizione che colpisce 6,5 milioni di donne negli Stati Uniti, caratterizzata dalla crescita del tessuto uterino al di fuori dell'utero, provocando dolore e problemi di fertilità.
Lisata Therapeutics (Nasdaq: LSTA) ha firmado un acuerdo de investigación patrocinada con la Universidad de Cincinnati para estudiar certepetide combinado con bevacizumab para tratar la endometriosis. La investigación tiene como objetivo aprovechar el enfoque selectivo de certepetide hacia el tejido endometrial a través de los receptores de integrinas en la superficie y neuropilina-1. Aunque el bevacizumab ha mostrado eficacia en el tratamiento de la endometriosis, sus altos requerimientos de dosificación causan efectos secundarios sistémicos. La asociación se dirige a la endometriosis, una condición que afecta a 6,5 millones de mujeres en EE. UU., caracterizada por el crecimiento del tejido uterino fuera del útero, causando dolor y problemas de fertilidad.
리사타 테라퓨틱스 (Nasdaq: LSTA)는 신시내티 대학교와 협력하여 certepetide와 bevacizumab을 결합한 치료법을 연구하는 후원 연구 협정에 들어갔습니다. 이 연구는 표면 인테그린과 뉴로필린-1 수용체를 통해 자궁내막 조직에 대한 certepetide의 선택적 타겟팅을 활용하는 것을 목표로 하고 있습니다. bevacizumab이 자궁내막증 치료에서 효과를 보였지만, 높은 복용량 요구량은 전신적인 부작용을 일으킵니다. 이 파트너십은 통증과 불임 문제를 일으키는 유착된 자궁 조직의 성장으로 특징지어지는 650만 명의 미국 여성에게 영향을 미치는 상태인 자궁내막증에 초점을 두고 있습니다.
Lisata Therapeutics (Nasdaq: LSTA) a signé un accord de recherche sponsorisé avec l'Université de Cincinnati pour étudier certepetide combiné avec bevacizumab pour le traitement de l'endométriose. La recherche vise à tirer parti du ciblage sélectif de certepetide sur le tissu endométrial via les récepteurs d'intégrine de surface et de neuropiline-1. Bien que le bevacizumab ait démontré son efficacité dans le traitement de l'endométriose, ses exigences en matière de dose élevée entraînent des effets secondaires systémiques. Le partenariat cible l'endométriose, condition touchant 6,5 millions de femmes aux États-Unis, caractérisée par la croissance du tissu utérin en dehors de l'utérus, causant des douleurs et des problèmes de fertilité.
Lisata Therapeutics (Nasdaq: LSTA) hat eine geförderte Forschungsvereinbarung mit der Universität Cincinnati geschlossen, um certepetide in Kombination mit bevacizumab zur Behandlung von Endometriose zu untersuchen. Ziel der Forschung ist es, die selektive Ansprache von Endometriumgewebe durch certepetide über die Oberflächenintegrin- und Neuropilin-1-Rezeptoren zu nutzen. Während Bevacizumab sich als wirksam bei der Behandlung von Endometriose erwiesen hat, verursachen die hohen Dosierungsanforderungen systemische Nebenwirkungen. Die Partnerschaft richtet sich an Endometriose, eine Erkrankung, die 6,5 Millionen Frauen in den USA betrifft und durch das Wachstum von Gebärmutterschleimhautgewebe außerhalb der Gebärmutter gekennzeichnet ist, was zu Schmerzen und Fruchtbarkeitsproblemen führt.
- Strategic research partnership with University of Cincinnati expands certepetide's potential applications beyond oncology
- Target market of 6.5 million patients in the U.S. alone represents significant commercial opportunity
- Certepetide's selective targeting mechanism could potentially reduce side effects compared to existing treatments
- Still in preclinical stage, indicating long development timeline before potential commercialization
- Research outcomes and efficacy remain uncertain
Insights
This preclinical research agreement represents a strategic expansion into a significant new therapeutic area for Lisata. The combination of certepetide with bevacizumab could potentially address a critical limitation in current endometriosis treatment. Bevacizumab's proven efficacy is hampered by systemic side effects, but certepetide's selective targeting mechanism could enable lower, safer dosing while maintaining therapeutic effectiveness.
The
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab
BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. Bevacizumab has previously demonstrated efficacy in treating endometriosis; however, the required dosage levels are associated with systemic side effects, limiting its use in otherwise healthy young women. Under the agreement, the University of Cincinnati will conduct the research, while Lisata will provide both funding and certepetide.
“We are pleased to have entered into a strategic scientific partnership with the University of Cincinnati to investigate the potential therapeutic applications of certepetide beyond oncology,” stated Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Lisata. “Given the selective targeting of endometrial tissue by certepetide due to its interaction with the surface integrin and neuropilin-1 receptors, we believe the combination of certepetide and bevacizumab could potentially offer an effective and targeted treatment for endometriosis.”
“We're excited to join forces with Lisata to explore the potential of certepetide for endometriosis,” stated Katherine Burns, PhD, Associate Professor at the University of Cincinnati College of Medicine. “By combining our expertise and resources, we aim to uncover insights that could change the treatment and management of endometriosis.”
Endometriosis, a debilitating condition affecting 6.5 million women in the U.S. alone1, occurs when uterine tissue grows outside the uterus and attaches to other organs. This can result in severe pain, infertility, and other reproductive health issues, as well as nausea, depression, and anxiety. Despite its prevalence, endometriosis remains underdiagnosed and misunderstood, with limited treatment options often requiring invasive surgical procedures. Researchers are actively working to better understand its causes and develop innovative therapies, with the goal of improving the lives of those affected by this condition.
______________________________________
1 Ellis, K., Munro, D., & Clarke, J. (2022). Endometriosis Is Undervalued: A Call to Action. Frontiers in global women's health, 3, 902371. https://doi.org/10.3389/fgwh.2022.902371
About Certepetide
Certepetide is an investigational drug designed to selectively activate the C-end rule active transport mechanism in a tissue-specific manner, resulting in systemically co-administered agents more efficiently penetrating and accumulating in the tissue. To date, certepetide has demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing oncology clinical trials designed to demonstrate its ability to enhance the effectiveness of standard-of-care chemotherapy for pancreatic cancer, as well as the combination of chemotherapy and immunotherapy in a variety of solid tumors. Beyond its promising applications in oncology, certepetide's unique mechanism of action has the potential to be explored in various non-oncology settings. Its ability to selectively target specific tissues could offer new therapeutic possibilities for a range of diseases. Certepetide has been awarded Fast Track designation (U.S.) and Orphan Drug Designation for pancreatic cancer (U.S. and E.U.), as well as Orphan Drug Designation for glioma, osteosarcoma, and cholangiocarcinoma (U.S.). Additionally, certepetide has received Rare Pediatric Disease Designation for osteosarcoma (U.S.).
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones during the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
About University of Cincinnati
Founded in 1819, the University of Cincinnati ranks among the nation’s best urban public research universities. Home to more than 53,000 students, 11,000 faculty and staff and 332,000 alumni, UC combines a Top 35 public research university with a physical setting The New York Times calls “the most ambitious campus design program in the country.” With the launch of Next Lives Here, the Cincinnati Innovation District, a
Forward-Looking Statements
This communication contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding the Company’s clinical development programs are forward-looking statements. In addition, when or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Lisata or its management, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, the potential efficacy of certepetide combined with bevacizumab as a treatment for patients with endometriosis; and certepetide’s potential in oncology and non-oncology applications. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: results observed from a single patient case study are not necessarily indicative of final results and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the safety and efficacy of Lisata’s product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in Lisata’s clinical programs, Lisata’s ability to finance its operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of Lisata’s scientific studies, Lisata’s ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in Lisata’s markets, the ability of Lisata to protect its intellectual property rights; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Lisata’s Annual Report on Form 10-K filed with the SEC on February 29, 2024, and in other documents filed by Lisata with the Securities and Exchange Commission. Except as required by applicable law, Lisata undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether because of new information, future events or otherwise.
Lisata Therapeutics Contact:
Investors:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
University of Cincinnati Contact:
Megan Burgasser
Public Information Officer
Phone: 513-545-5616
Email: megan.burgasser@uc.edu
FAQ
What is the purpose of Lisata Therapeutics' (LSTA) research agreement with University of Cincinnati?
How does Lisata's (LSTA) certepetide target endometrial tissue?
What is the market potential for Lisata's (LSTA) endometriosis treatment?
Why is Lisata (LSTA) combining certepetide with bevacizumab?
